Ultrasound Historical Financial Summary
Higher Commercial and R&D Spend to Drive Growth
Executing on Precision
Care Strategy
Prioritizing Fastest-Growing Areas
Est. CAGR '22-'25
Premium CT / PCCT
-10%-b)
$1B + 2022E R&D
Cardio 3-D Image-guided Therapies
-15%
Driving Organic
Handheld Ultrasound
-20%
Oncology MI / Theranostics.
20%+
35%+ NPI vitality-a)
Revenue
Growth* &
Adjusted EBIT*
MR Platforming
~5-7%
Al Solutions and Edison™ Platform
25%+-c)
Growing, Focused R&D Driving Innovation Releases Every 12-18 Months-d)
* Non-GAAP Financial Measure
(a - Defined as percentage of product orders received in 2021 in Imaging, Ultrasound and PCS segments for products introduced
in the last 12 months.
(b - Premium CT / Photon-Counting CT CAGR pertains to '18-'30.
(c-Refers to GEHC Edison™ platform and apps revenue growth rate. All other metrics refer to end market growth rates.
(d-For most product lines.
© 2022, General Electric Company. Proprietary information. All rights reserved.
24
24View entire presentation